August 2019
Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.
Combination immunotherapy study for renal cancer
at Providence Cancer Institute
Credit: National Institute of Allergy and Infectious Diseases, NIH
T-cell checkpoint antibodies have revolutionized immunotherapy for cancer, including renal cancer. A new phase III study open at Providence Cancer Institute will evaluate the effectiveness of checkpoint immunotherapy in combination with an investigational cytokine agent in patients with advanced renal cancer, compared to standard-of-care targeted therapy.
All current open studies:
Find additional studies for many types of cancer in Multiple Tumor Types .
New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.